Weiss Multi-Strategy Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,480	Closed	-$1.51M	–	307
2023 Q4	$1.51M	Buy	+11,480	New	+$1.32M	0.04%	397
2022 Q3	–	Sell	-27,070	Closed	-$2.64M	–	724
2022 Q2	$2.64M	Buy	27,070 +7,070	+35%	+$653K	0.08%	339
2022 Q1	$1.88M	Sell	20,000 -14,105	-41%	-$1.2M	0.04%	415
2021 Q4	$2.9M	Buy	34,105 +1,161	+4%	+$107K	0.07%	325
2021 Q3	$3.16M	Buy	32,944 +720	+2%	+$68K	0.07%	335
2021 Q2	$3.14M	Buy	32,224 +1,152	+4%	+$110K	0.07%	343
2021 Q1	$3.02M	Sell	31,072 -4,159	-12%	-$436K	0.07%	346
2020 Q4	$3.38M	Sell	35,231 -5,028	-12%	-$486K	0.07%	330
2020 Q3	$3.87M	Sell	40,259 -2,241	-5%	-$259K	0.1%	268
2020 Q2	$5.18M	Sell	42,500 -8,379	-16%	-$926K	0.15%	206
2020 Q1	$4.4M	Sell	50,879 -2,121	-4%	-$208K	0.17%	172
2019 Q4	$5.7M	Buy	53,000 +3,000	+6%	+$314K	0.09%	282
2019 Q3	$4.51M	Sell	50,000 -15,000	-23%	-$1.4M	0.09%	269
2019 Q2	$5.49M	Hold	65,000	–	–	0.15%	160
2019 Q1	$5.73M	Sell	65,000 -1,000	-2%	-$83.6K	0.14%	181
2018 Q4	$4.71M	Sell	66,000 -19,000	-22%	-$1.82M	0.2%	135
2018 Q3	$10.5M	Sell	85,000 -2,319	-3%	-$263K	0.28%	89
2018 Q2	$8.58M	Buy	87,319 +12,319	+16%	+$1.1M	0.21%	138
2018 Q1	$6.22M	Buy	75,000 +33,000	+79%	+$2.79M	0.2%	140
2017 Q4	$3.26M	Buy	42,000 +7,000	+20%	+$477K	0.08%	261
2017 Q3	$2.15M	Buy	35,000 +4,000	+13%	+$211K	0.08%	297
2017 Q2	$1.43M	Sell	31,000 -1,500	-5%	-$72.8K	0.06%	332
2017 Q1	$1.41M	Sell	32,500 -3,500	-10%	-$150K	0.06%	343
2016 Q4	$1.39M	Buy	36,000 +5,000	+16%	+$226K	0.07%	252
2016 Q3	$1.57M	Sell	31,000 -347	-1%	-$17.3K	0.1%	241
2016 Q2	$1.43M	Buy	31,347 +347	+1%	+$16K	0.11%	222
2016 Q1	$1.23M	Buy	31,000 +14,000	+82%	+$556K	0.05%	320
2015 Q4	$962K	Hold	17,000	–	–	0.07%	244
2015 Q3	$676K	Buy	17,000 +1,500	+10%	+$72.5K	0.03%	294
2015 Q2	$740K	Buy	15,500 +6,000	+63%	+$254K	0.03%	341
2015 Q1	$377K	Sell	9,500 -500	-5%	-$17.9K	0.02%	385
2014 Q4	$223K	Sell	10,000 -10,000	-50%	-$189K	0.01%	375
2014 Q3	$313K	Hold	20,000	–	–	0.01%	472
2014 Q2	$297K	Buy	+20,000	New	+$282K	0.01%	649
2014 Q1	–	Sell	-18,750	Closed	-$175K	–	1069
2013 Q4	$175K	Buy	+18,750	New	+$183K	﹤0.01%	920
2013 Q3	–	Sell	-150,000	Closed	-$2.01M	–	963
2013 Q2	$2.01M	Buy	+150,000	New	+$1.84M	0.06%	322

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's NBIX Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 11,480 shares — an estimated $1.51M sold.

Weiss Multi-Strategy Advisers first reported a position in NBIX in Q2 2013 and held it in 36 quarters. The position peaked at $10.5M in Q3 2018. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 11,480 Neurocrine Biosciences shares in Q1 2024, an estimated $1.51M.
Weiss Multi-Strategy Advisers first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 36 quarters.
Weiss Multi-Strategy Advisers's Neurocrine Biosciences position peaked at $10.5M in Q3 2018.
589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.